Business
Elanco Investor Day Defines New Era as Sustainable Growth Company
Elanco Animal Health Incorporated (NYSE: ELAN) hosts its first Investor Day in five years this morning, marking a pivotal moment as the company further defines its new era of sustainable growth and long-term value creation. Elanco will detail how its consistent Innovation, Portfolio and Productivity (IPP) strategy is designed to guide the company's transformation to a sustainable growth company, delivering consistent mid-single digit organic constant currency revenue growth and adjusted EBITDA m
About this update from Elanco Animal Health Incorporated
[{"type":"list","items":[{"val":[{"type":"text","content":"Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to <3x in 2027, with a long-term target of 2.0x to 2.5x.","length":364,"tagName":"p"}]},{"val":[{"type":"text","content":"Expects innovation revenue contribution of approximately $1.1 billion in 2026, with aims to double revenue from 'Big 6' blockbuster potential products by 2028.","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"Discusses 10+ major innovation products in development phase with 5-6 blockbuster-potential approvals expected between 2026 and 2031. Two in-house technology development platforms contributing to next wave innovation pipeline: monoclonal antibody discovery and immuno-therapeutics.","length":286,"tagName":"p"}]},{"val":[{"type":"text","content":"Announces intended closure of German animal R&D facility and targeted reduction to manufacturing workforce along with increased investment in Elanco Innovation Laboratories at its Indiana headquarters and continued investments in U.S. manufacturing as we have greater clarity on U.S. tariffs and accelerated USDA regulatory timelines. This includes an accelerated conditional approval pathway for a potential first-in-class immuno-therapeutic major pet blockbuster, expected in the next 2-3 years.","length":506,"tagName":"p"}]},{"val":[{"type":"text","content":"Announces technical sections complete for Befrena™ (tirnovetmab), the company's IL-31 injectable monoclonal antibody for canine dermatitis, with expected differentiation in efficacy, convenience and value. Remains cautiously optimistic that administrative review and approval will be complete in Q4 2025.","length":313,"tagName":"p"}]},{"val":[{"type":"text","content":"Expects $200 to $250 million in adjusted EBITDA savings from Elanco Ascend by 2030.","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Announces restructuring as part of Elanco Ascend to support margin expansion, optimize footprint and further increase innovation capacity. Creates an expected restructuring charge of approximately $175 million, of which...